Users Stopping Weight-Loss Injections Regain Pounds Far More Rapidly Compared to People Using Diet and Exercise

Fresh analysis reveals that individuals who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.

Findings released in a major medical journal demonstrates that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.

"People using these treatments must be aware of the risk of quick rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.

Such speed of recovery implies a return to pre-treatment mass within about 18 months.

Weighing Therapies

The research, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with other pills.

Scientists emphasize that people who shed pounds through lifestyle changes alone generally see a more gradual creep back—perhaps 100 grams monthly—post-intervention.

The Reason for the Rapid Rebound

Nutrition scientists suggest the way of the jabs is key to understanding the heightened rebound.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this medication leads to appetite is unsuppressed, making overeating far more likely."

A Lifelong Disease?

Health authorities suggest the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.

Professionals say that, considering the high risk of weight regain, the treatment is often life-long.

This opinion is supported by pharmaceutical companies, who say that the findings "underscore the chronic nature of obesity," comparing it to managing conditions like high blood pressure.

Patient Accounts

Individuals who have come off the medication report a sudden resurgence of appetite.

"It was like a trigger that goes on and I was suddenly starving," described a patient.

This challenge is exacerbated if users have not developed sustainable lifestyle or habit modifications during treatment.

Significant Interest

Figures indicate that millions of adults in the UK have tried these injections in the last 12 months, with demand being substantial.

• Adoption is more common among females compared to males.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion obtain the medications through private healthcare rather than public health services.

In conclusion, researchers stress that while these medications are effective agents for shedding pounds, they are not a permanent fix and long-term success likely depends on integrated lifestyle support.